Contineum Therapeutics (CTNM) vs MapLight Therapeutics (MPLT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Contineum Therapeutics is the larger company by market cap ($503.4 million vs $490.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CTNM | MPLT |
|---|---|---|
| Share price | $13.38 | $8.83 |
| Market cap | $503.37M | $490.73M |
| 1-day change | +1.52% | -3.50% |
| YTD return | +17.06% | -49.73% |
| 1-year return | +10.03% | — |
| EPS (TTM) | $-1.75 | $-6.03 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.79 | $40.43 |
| 52-week low | $8.60 | $8.71 |
| Distance from 52-week high | -24.77% | -78.16% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +67.64% | +200.57% |
| Average volume | 520.62K | 851.70K |
| Shares outstanding | 32.96M | 52.85M |
| Employees | 51 | 133 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Contineum Therapeutics
CTNM stock →Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain.
Health Care · Biotechnology: Pharmaceutical Preparations · 51 employees
About MapLight Therapeutics
MPLT stock →MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 133 employees
CTNM vs MPLT FAQ
Which is bigger, Contineum Therapeutics or MapLight Therapeutics?
Contineum Therapeutics (CTNM) is larger, with a market capitalization of $503.37M compared with $490.73M for MapLight Therapeutics (MPLT).
Are Contineum Therapeutics and MapLight Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.